An optimized gene transfection system in WERI-Rb1 cells

Liu,Ying; Fan,Zhigang; Li,Kang; Deng,Fei; Xiong,Yunfan; Liang,Meixin; Ge,Jian

doi:10.3892/ijmm.2017.3058

An optimized gene transfection system in WERI-Rb1 cells

Authors:
- Ying Liu
- Zhigang Fan
- Kang Li
- Fei Deng
- Yunfan Xiong
- Meixin Liang
- Jian Ge
View Affiliations

Affiliations: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, P.R. China
Published online on: July 6, 2017 https://doi.org/10.3892/ijmm.2017.3058
Pages: 801-813
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathogenesis of Rb1 gene inactivation indicates that gene therapy could be a promising treatment for retinoblastoma. An appropriate gene transfer system is the basis for successful gene therapy; however, little attention has been given to an effective gene transfer system for retinoblastoma therapy in previous studies. This study was designed to provide an optimized transgene system for WERI‑Rb1 cells (W-RBCs). Green fluorescent protein (GFP) was adopted as a reporter. Four classic viral vectors based on retroviruses, recombinant adeno-associated viruses (rAAV2, rAAV2/1), lentiviruses (LVs) and a novel non-viral vector X-treme HP reagent were adopted for W-RBC gene transfection. The efficacy and cytotoxicity were comprehensively compared among the different vectors through GFP expression and the trypan blue exclusion test. Furthermore, the serum and cell culture status were also optimized for better transfection. Cells transfected by rAAV2/1 expressed more GFP protein and exhibited less staining with trypan blue, compared to the rAAV2 counterpart. However, in comparison to the retroviral group, both the rAAV2/1 and LV groups had considerably less GFP+ cells. Interestingly, the X-treme HP presented a similar GFP transfection capacity to the retroviral vector, but with a much lower cytotoxicity. Furthermore, there were more GFP+ cells in a suspended condition than that in an adherent culture. Moreover, cells in a serum-positive system expressed more GFP, while cells in a serum-free system showed lower GFP expression and higher cytotoxicity. In conclusion, the retroviral vector and the X-treme HP are effective for W-RBC gene transfection, while the X-treme HP is more preferable due to its lower cytotoxicity. Moreover, the suspended cell culture system is superior to the adherent system, and the serum protects cell viability and facilitates the gene transfection of W-RBCs. This study presents an effective, convenient, and low toxic transfection system for gene delivery in W-RBCs and provides a promising system for further gene therapy of retinoblastoma.

View Figures

View References

1	Bishop JO and Madson EC: Retinoblastoma. Review of the current status. Surv Ophthalmol. 19:342–366. 1975.PubMed/NCBI
2	Shields CL, Meadows AT, Leahey AM and Shields JA: Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 24:849–862. 2004. View Article : Google Scholar : PubMed/NCBI
3	Garcia D and Quintyn JC: Treatment of retinoblastoma by radiation therapy. Sixty-six years later. J Fr Ophtalmol. 36:87–88. 2013.In French. View Article : Google Scholar
4	Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE and Fraumeni JF Jr: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 99:24–31. 2007. View Article : Google Scholar : PubMed/NCBI
5	Mouw KW, Sethi RV, Yeap BY, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Munzenrider JE, Adams J, Grabowski E, et al: Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys. 90:863–869. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY and Hurwitz RL: Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol. 23:7927–7935. 2005. View Article : Google Scholar : PubMed/NCBI
7	Hurwitz MY, Marcus KT, Chévez-Barrios P, Louie K, Aguilar-Cordova E and Hurwitz RL: Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther. 10:441–448. 1999. View Article : Google Scholar : PubMed/NCBI
8	Nichols KE, Walther S, Chao E, Shields C and Ganguly A: Recent advances in retinoblastoma genetic research. Curr Opin Ophthalmol. 20:351–355. 2009. View Article : Google Scholar : PubMed/NCBI
9	Giacinti C and Giordano A: RB and cell cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
10	Jia RB, Zhang P, Zhou YX, Song X, Liu HY, Wang LZ, Luo M, Lu J, Ge SF and Fan XQ: VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 39:108–115. 2007. View Article : Google Scholar : PubMed/NCBI
11	Jia RB, Fan XQ, Wang XL, Zhang XQ, Zhang P and Lu J: Inhibition of VEGF expression by plasmid-based RNA interference in the retinoblastoma cells. Zhonghua Yan Ke Za Zhi. 43:493–498. 2007.In Chinese. PubMed/NCBI
12	Chau KY and Ono SJ: Gene transfer into retinoblastoma cells. Biotechniques. 26:444–446. 1999.PubMed/NCBI
13	Adachi M, Brooks SE, Stein MR, Franklin BE and Caccavo FA: Destruction of human retinoblastoma after treatment by the E variant of encephalomyocarditis virus. J Neurooncol. 77:233–240. 2006. View Article : Google Scholar : PubMed/NCBI
14	Di Polo A and Farber DB: Rod photoreceptor-specific gene expression in human retinoblastoma cells. Proc Natl Acad Sci USA. 92:4016–4020. 1995. View Article : Google Scholar : PubMed/NCBI
15	Herman MM, Perentes E, Katsetos CD, Darcel F, Frankfurter A, Collins VP, Donoso LA, Eng LF, Marangos PJ, Wiechmann AF, et al: Neuroblastic differentiation potential of the human retinoblastoma cell lines Y-79 and WERI-Rb1 maintained in an organ culture system. An immunohistochemical, electron microscopic, and biochemical study. Am J Pathol. 134:115–132. 1989.PubMed/NCBI
16	Muncaster MM, Cohen BL, Phillips RA and Gallie BL: Failure of RB1 to reverse the malignant phenotype of human tumor cell lines. Cancer Res. 52:654–661. 1992.PubMed/NCBI
17	Daya S and Berns KI: Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 21:583–593. 2008. View Article : Google Scholar : PubMed/NCBI
18	Al-Saikhan FI: The gene therapy revolution in ophthalmology. Saudi J Ophthalmol. 27:107–111. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, Hunt DM and Bhattacharya SS: Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet. 5:591–594. 1996. View Article : Google Scholar : PubMed/NCBI
20	Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N and Hauswirth WW: Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA. 94:6916–6921. 1997. View Article : Google Scholar : PubMed/NCBI
21	Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al: Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 358:2240–2248. 2008. View Article : Google Scholar : PubMed/NCBI
22	Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, et al: Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther. 19:326–334. 2011. View Article : Google Scholar
23	Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, et al: Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 19:260–265. 2011. View Article : Google Scholar :
24	Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, Wilson JM and Bennett J: Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a model. Hum Mol Genet. 10:3075–3081. 2001. View Article : Google Scholar : PubMed/NCBI
25	Pang J, Cheng M, Haire SE, Barker E, Planelles V and Blanks JC: Efficiency of lentiviral transduction during development in normal and rd mice. Mol Vis. 12:756–767. 2006.PubMed/NCBI
26	Mátrai J, Chuah MK and VandenDriessche T: Recent advances in lentiviral vector development and applications. Mol Ther. 18:477–490. 2010. View Article : Google Scholar : PubMed/NCBI
27	Miyoshi H, Takahashi M, Gage FH and Verma IM: Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA. 94:10319–10323. 1997. View Article : Google Scholar : PubMed/NCBI
28	Garson K, Gamwell LF, Pitre EM and Vanderhyden BC: Technical challenges and limitations of current mouse models of ovarian cancer. J Ovarian Res. 5:392012. View Article : Google Scholar : PubMed/NCBI
29	Tosetti F, Venè R, Arena G, Morini M, Minghelli S, Noonan DM and Albini A: N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol. 63:565–573. 2003. View Article : Google Scholar : PubMed/NCBI
30	Cepko CL: Emerging gene therapies for retinal degenerations. J Neurosci. 32:6415–6420. 2012. View Article : Google Scholar : PubMed/NCBI
31	Day TP, Byrne LC, Schaffer DV and Flannery JG: Advances in AAV vector development for gene therapy in the retina. Adv Exp Med Biol. 801:687–693. 2014. View Article : Google Scholar : PubMed/NCBI
32	Janson CG, McPhee SW, Leone P, Freese A and During MJ: Viral-based gene transfer to the mammalian CNS for functional genomic studies. Trends Neurosci. 24:706–712. 2001. View Article : Google Scholar : PubMed/NCBI
33	Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, Almeida D, Liu A, Jhanwar SC, Abramson DH and Cobrinik D: Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell. 137:1018–1031. 2009. View Article : Google Scholar : PubMed/NCBI
34	Koirala A, Conley SM and Naash MI: A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 34:7158–7167. 2013. View Article : Google Scholar : PubMed/NCBI
35	Boylan NJ, Kim AJ, Suk JS, Adstamongkonkul P, Simons BW, Lai SK, Cooper MJ and Hanes J: Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine. Biomaterials. 33:2361–2371. 2012. View Article : Google Scholar :
36	McIntosh JH, Cochrane M, Cobbold S, Waldmann H, Nathwani SA, Davidoff AM and Nathwani AC: Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther. 19:78–85. 2012. View Article : Google Scholar
37	VandenDriessche T: Muscling through AAV immunity. Blood. 114:2009–2010. 2009. View Article : Google Scholar : PubMed/NCBI
38	Harvey AR, Kamphuis W, Eggers R, Symons NA, Blits B, Niclou S, Boer GJ and Verhaagen J: Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: A comparison with lentiviral vectors. Mol Cell Neurosci. 21:141–157. 2002. View Article : Google Scholar : PubMed/NCBI
39	Daly G and Chernajovsky Y: Recent developments in retroviral-mediated gene transduction. Mol Ther. 2:423–434. 2000. View Article : Google Scholar : PubMed/NCBI
40	Liu Y and Deisseroth A: Tumor vascular targeting therapy with viral vectors. Blood. 107:3027–3033. 2006. View Article : Google Scholar
41	Ramamoorth M and Narvekar A: Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 9:GE01–GE06. 2015.PubMed/NCBI
42	Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR and Anderson DG: Non-viral vectors for gene-based therapy. Nat Rev Genet. 15:541–555. 2014. View Article : Google Scholar : PubMed/NCBI
43	Chan CL, Ewert KK, Majzoub RN, Hwu YK, Liang KS, Leal C and Safinya CR: Optimizing cationic and neutral lipids for efficient gene delivery at high serum content. J Gene Med. 16:84–96. 2014. View Article : Google Scholar : PubMed/NCBI